SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80 million in a Series A+ financing round co-led by Tencent Investment and YuanBio Venture Capital. The funding round also saw participation from Northern Light Venture Capital, C&D Emerging Industry Equity Investment, Yuanhe Holding, Shanghai Healthcare Capital, Shenzhen Capital Group, and TEDA Venture Capital, alongside existing investors such as Qiming Venture Partners, Alwin Capital, K2VC, and TF Capital.
The capital will be allocated to accelerate the Investigational New Drug (IND) filing process and advance clinical studies across its therapeutic pipelines, which target cardiovascular and metabolic diseases, immune-mediated disorders, and more. Additionally, the funds will support the development of an extrahepatic delivery platform and further drug development initiatives.
Founded in 2021, SanegeneBio operates in both China and the U.S. and leverages a proprietary chemical modification platform along with hepatic and extrahepatic delivery systems, allowing for tissue-specific delivery of a diverse array of RNA therapeutics aimed at effectively silencing disease-causing genes.- Flcube.com
